The method of treating drug resistant mycobacterium tuberculosis infection
Номер патента: EP1296680A2
Опубликовано: 02-04-2003
Автор(ы): Bakulesh Mafatlal Khamar
Принадлежит: Individual
Опубликовано: 02-04-2003
Автор(ы): Bakulesh Mafatlal Khamar
Принадлежит: Individual
Реферат: Multidrug resistance to anti-tuberculous drugs poses threat in the treatment of tuberculosis. These strains are resistant to at least tow first line anti-tuberculous drugs such as INH and rifampicin. Frequently, such MDR strains show resistance to all commonly used first-line agents i.e INH, rifampicin, streptomycin, ethambutol and pyrazinamide. Isoniazid is the most widely used anti-tuberculous drug. Resistance to isoniazid can occur by increased expression on inhA or by mutations that lower the enzyme's affinity to NADH. Mutations in katG, which encodes catalase peroxidase, is the most common source of resistance. Another mechanism of isoniazid resistance occurs by defects in NADH dehydrogenase (Ndh) of the respiratory chain. Increases expression of AhpC has been suggested as another mechanism of INH resistance in mycobacteria. The present invention provides method of treating drug resistance for Mycobacterium tuberculosis infection. According to present invention, a method is provided to employ penicillin with INH. This reduces the MIC of INH and makes resistant organisms sensitive. The level of penicillins required for reversal of INH resistance is known to be achieved and maintained by therapeutic doses of penicillins.
The method of treating drug resistant mycobacterium tuberculosis infection
Номер патента: WO2002000163A3. Автор: Mafatlal Khamar Bakulesh. Владелец: Mafatlal Khamar Bakulesh. Дата публикации: 2002-04-18.